Biotechnologies Assets SA (BST.MC)

EUR 0.29

(-5.84%)

Revenue Summary of Biotechnologies Assets SA

Biotechnologies Assets SA's latest annual revenue in 2023 was 3.9 Million EUR , up 37.79% from previous year.
Biotechnologies Assets SA's latest quarterly revenue in 2023 FY was 3.6 Million EUR , up 37.79% from previous quarter.
Biotechnologies Assets SA reported a annual revenue of 2.61 Million EUR in annual revenue 2022, down -15.28% from previous year.
Biotechnologies Assets SA reported a annual revenue of 3.08 Million EUR in annual revenue 2021, up 22.21% from previous year.
Biotechnologies Assets SA reported a quarterly revenue of 821.11 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
Biotechnologies Assets SA reported a quarterly revenue of 1.13 Million EUR for 2023 Q3, up 38.0% from previous quarter.

Annual Revenue Chart of Biotechnologies Assets SA (2023 - 2010)

Historical Annual Revenue of Biotechnologies Assets SA (2023 - 2010)

Year	Revenue	Revenue Growth
2023	3.9 Million EUR	37.79%
2022	2.61 Million EUR	-15.28%
2021	3.08 Million EUR	22.21%
2020	2.52 Million EUR	-93.96%
2019	41.82 Million EUR	79.38%
2018	23.31 Million EUR	876.06%
2017	2.38 Million EUR	82.04%
2016	1.31 Million EUR	24.94%
2015	1.05 Million EUR	-44.15%
2014	1.88 Million EUR	116.04%
2013	870.45 Thousand EUR	96.42%
2012	443.17 Thousand EUR	53.27%
2011	289.15 Thousand EUR	109.57%
2010	137.97 Thousand EUR	0.0%

Year	Revenue	Revenue Growth
2023 FY	3.6 Million EUR	37.79%
2023 Q2	821.11 Thousand EUR	0.0%
2023 Q3	1.13 Million EUR	38.0%
2023 Q1	821.11 Thousand EUR	-8.68%
2023 Q4	1.13 Million EUR	0.0%
2022 FY	2.61 Million EUR	-15.28%
2022 Q4	899.13 Thousand EUR	0.0%
2021 FY	3.08 Million EUR	22.21%
2020 FY	2.52 Million EUR	-93.96%
2019 FY	41.82 Million EUR	79.38%
2018 FY	23.31 Million EUR	876.06%
2017 FY	2.38 Million EUR	82.04%
2016 FY	1.31 Million EUR	24.94%
2015 FY	1.05 Million EUR	-44.15%
2014 FY	1.88 Million EUR	116.04%
2013 FY	870.45 Thousand EUR	96.42%
2012 FY	443.17 Thousand EUR	53.27%
2011 FY	289.15 Thousand EUR	109.57%
2010 FY	137.97 Thousand EUR	0.0%

Peer Revenue Comparison of Biotechnologies Assets SA

Name	Revenue	Revenue Difference
Atrys Health, S.A.	201.56 Million EUR	98.061%
Oryzon Genomics S.A.	14.19 Million EUR	72.46%
Pharma Mar, S.A.	158.15 Million EUR	97.529%
Laboratorios Farmaceuticos Rovi, S.A.	829.5 Million EUR	99.529%